Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for GLAXO
Revenue projections for GLAXO

Revenues for GLAXO are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 0.00000
forwardPE 34.25237
debtToEquity 2.09100
earningsGrowth 0.28600
revenueGrowth 0.09700
grossMargins 0.63639
operatingMargins 0.33711
trailingEps 60.28000
forwardEps 68.55000

GLAXO's positive gross and operating margins suggest the company is performing profitably. These margins reflect efficient cost management and strong revenue generation, signaling healthy financial performance and operational effectiveness.
GlaxoSmithKline Pharmaceuticals Limited's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for GLAXO
Price projections for GLAXO

GlaxoSmithKline Pharmaceuticals Limited's price projections have been consistently revised upward, suggesting that analysts are becoming increasingly optimistic about the company's future. This trend reflects confidence in GlaxoSmithKline Pharmaceuticals Limited's ability to achieve strong financial results.

Recommendation changes over time:

Recommendations trend for GLAXO
Recommendations trend for GLAXO


The recent buy bias from analysts suggests GLAXO is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, GLAXO appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.